3rd Annual Hematologic Malignancies Symposium

 

3rd Annual Hematologic Malignancies Symposium
A

IDH Inhibitors in MDS: Frequency & Prognosis, Mutations, Therapy Outcomes, Enasidenib/Ivosidenib, HMA Combinations, Options for Clonal Escape

By 3rd Annual Hematologic Malignancies Symposium FEATURING Andrew Wei
By 3rd Annual Hematologic Malignancies Symposium FEATURING Andrew Wei
0 views
April 7, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
Videos
26:33
3rd Annual Hematologic Malignancies Symposium

2021 Updates on FLT3m Frontline AML: Does HiDAC+Chemo Provide OS Ben…

Feat. A. Perl
07:34
3rd Annual Hematologic Malignancies Symposium

2021 Updates on FLT3m R/R AML: What Is the Current Standard of Care?…

Feat. A. Perl
15:35
3rd Annual Hematologic Malignancies Symposium

How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve O…

Feat. G. Roboz
22:10
3rd Annual Hematologic Malignancies Symposium

MD Anderson Update on the Role of IDH Inhibition in AML: Targeted Th…

Feat. C. DiNardo
26:23
3rd Annual Hematologic Malignancies Symposium

HMA Resistance & Treatment After HMT Failure in MDS: Aza vs. CCR…

Feat. H. Carraway
15:41
3rd Annual Hematologic Malignancies Symposium

IDH Inhibitors in MDS: Frequency & Prognosis, Mutations, Therapy…

Feat. A. Wei